ArticleImmunology1993
Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction.
Article in Immunology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Cardioprotective effects of the extracellular chaperone clusterin in acute myocardial infarction.European journal of clinical investigation · 2025Article
- Cardioprotection in cardiovascular surgery.Basic research in cardiology · 2024Review
- Clusterin is a Potential Therapeutic Target in Alzheimer's Disease.Molecular neurobiology · 2024Review
- The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing.International journal of molecular sciences · 2023Review
- Review
- Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications.Diagnostics (Basel, Switzerland) · 2020Review
- Early Elevation of Systemic Plasma Clusterin after Reperfused Acute Myocardial Infarction in a Preclinical Porcine Model of Ischemic Heart Disease.International journal of molecular sciences · 2020Article
- Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life.Frontiers in immunology · 2020Article
- Increased clusterin levels after myocardial infarction is due to a defect in protein degradation systems activity.Cell death & disease · 2019Article
- Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes.Heart failure reviews · 2018Review
- Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers.Journal of the American Heart Association · 2016Review
- The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart.Trends in molecular medicine · 2011Review
- Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3β signaling pathway.Experimental & molecular medicine · 2011Article
- Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium.Journal of clinical pathology · 2000Article
- Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis.The Journal of clinical investigation · 2000Article
- Apolipoprotein J/clusterin induction in myocarditis: A localized response gene to myocardial injury.The American journal of pathology · 1996Article
- Clusterin promotes the aggregation and adhesion of renal porcine epithelial cells.The Journal of clinical investigation · 1995Article
- Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.The American journal of pathology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clusterin is a multi-functional plasma glycoprotein that has been shown to inhibit formation of the complement membrane attack complex (MAC) by preventing the association of terminal complement complexes with target cell membranes. Recent studies have suggested that complement activation is involved in the development of tissue injury of myocardial infarction. In this study we observed that clusterin is selectively deposited in the infarcted areas of human myocardium. Clusterin deposits were observed in the heart tissue of 10 patients whose infarcted lesions were 8 hr to 14 days old, but not in patients who died from other causes. Clusterin co-localized with the MAC on the surface of damaged cardiomyocytes. In normal myocardium only endothelial lining of blood vessels occasionally stained positive for clusterin. The 80,000 MW clusterin was also detected by Western blot analysis in extracts of myocardial infarction lesions, but only faintly in extracts of normal heart. As clusterin has apparently failed in protecting myocardium against complement-mediated cell injury its main role might be to participate in the clearance of damaged and necrotic tissue together with the MAC.
Indexed as
Identifiers
8262547PMC1422180W2398655886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.